Daniel Joseph OConnell - 30 Jun 2021 Form 3 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role
President and CEO, Director
Signature
/s/ Katherine Denby, Attorney-in-Fact
Issuer symbol
ABOS
Transactions as of
30 Jun 2021
Net transactions value
$0
Form type
3
Filing time
30 Jun 2021, 18:51:03 UTC
Next filing
08 Jul 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ABOS Common Stock 1,419 30 Jun 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ABOS Series A Preferred Stock 30 Jun 2021 Common Stock 123 Direct F1
holding ABOS Warrant (Right to Buy) 30 Jun 2021 Common Stock 35 $2.01 Direct F2
holding ABOS Stock Option (Right to Buy) 30 Jun 2021 Common Stock 1,118 $4.47 Direct F2
holding ABOS Stock Option (Right to Buy) 30 Jun 2021 Common Stock 197 $22.39 Direct F2
holding ABOS Stock Option (Right to Buy) 30 Jun 2021 Common Stock 33,567 $4.47 Direct F2
holding ABOS Stock Option (Right to Buy) 30 Jun 2021 Common Stock 12,527 $4.47 Direct F2
holding ABOS Stock Option (Right to Buy) 30 Jun 2021 Common Stock 418,903 $0.7200 Direct F3
holding ABOS Stock Option (Right to Buy) 30 Jun 2021 Common Stock 1,186,346 $1.19 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series A Preferred Stock will automatically convert into one share of Common Stock of the Issuer upon the closing of the Issuer's initial public offering. The Series A Preferred Stock has no expiration date.
F2 Immediately exercisable.
F3 The shares underlying the option vest and become exercisable in 36 equal monthly installments beginning on November 19, 2018, such that the option shall be fully vested on October 19, 2021, subject to the Reporting Person providing continuous service to the Issuer on each such date.
F4 25% of the shares underlying the option shall vest and become exercisable on January 1, 2022; the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, such that the option shall be fully vested on January 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on each such date.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney